Tech Company Financing Transactions

Diasome Pharmaceuticals Funding Round

Devon Park Bioventures, Quaker Partners and BioAdvance Ventures joined a Series B funding round for Diasome Pharmaceuticals. The round closed on 4/15/2008.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

10000 Cedar Ave. 6
Cleveland, OH 44106
USA

Phone

(216) 444-7110

Website

www.diasome.com

Email Address

[email protected]

Overview

Diasome Pharmaceuticals, Inc. is a venture-backed biopharmaceutical company focused on novel insulin-based therapies for the improved treatment of diabetes. The Company was formed in 2004 and has completed multiple Phase II human studies of HDV-Insulin, its proprietary insulin targeting system.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Robert Geho

        

Chief Financial Officer

Helga Kautsky

        

Chief Scientific Officer

Blair Geho

        

Browse more venture capital transactions:

Prev: 4/15/2008: FrontStream Payments venture capital transaction
Next: 4/15/2008: Lanx venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary